Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T20:36:23.014Z.
Calculation as of: 2026-10-06T20:36:23.014Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d443e069440aa0ac5a32f25afa0d38c48efe58a411ec60778b8439bb1c5cf92a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Eledon Pharmaceuticals, Inc.
Market Cap
$189.11M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$190.07M
EV/Sales Ratio
N/A
TTM Avg
4.34x
3Y Avg
5.78x
5Y Avg
5.78x
Market Cap
$180.47M
EV/Sales Ratio
95.75x
TTM Avg
300.14x
3Y Avg
300.14x
5Y Avg
300.14x
Market Cap
$198.33M
EV/Sales Ratio
77.57x
TTM Avg
65.28x
3Y Avg
31.25x
5Y Avg
19.18x
Market Cap
$179.75M
EV/Sales Ratio
N/A
TTM Avg
307.72x
3Y Avg
307.72x
5Y Avg
307.72x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | $189.11M | N/A | N/A | N/A | N/A |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $190.07M | N/A | 4.34x | 5.78x | 5.78x |
| RxSight, Inc. (RXST)vs › | $192.49M | 1.49x | 2.17x | 8.61x | 10.27x |
| AN2 Therapeutics, Inc. (ANTX)vs › | $182.60M | N/A | N/A | N/A | N/A |
| Surrozen, Inc. (SRZN)vs › | $197.18M | 8.81x | 29.79x | 18.48x | 17.16x |
| Canton Strategic Holdings Inc (CNTN)vs › | $180.47M | 95.75x | 300.14x | 300.14x | 300.14x |
| Exagen Inc. (XGN)vs › | $197.87M | 2.80x | 1.99x | 1.51x | 1.29x |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $198.33M | 77.57x | 65.28x | 31.25x | 19.18x |
| Compass Therapeutics, Inc. (CMPX)vs › | $179.75M | N/A | 307.72x | 307.72x | 307.72x |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $179.26M | N/A | 35.88x | 65.08x | 86.67x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
